EP4431086A1 — Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide
Assigned to Adalvo Ltd · Expires 2024-09-18 · 2y expired
What this patent protects
The present invention relates to a pharmaceutical composition comprising (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl]butanamide or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof, which is free of a cyclodextrin agent …
USPTO Abstract
The present invention relates to a pharmaceutical composition comprising (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl]butanamide or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof, which is free of a cyclodextrin agent and free of a binding agent and to a process of the preparation thereof.
Drugs covered by this patent
- Briviact (BRIVARACETAM) · UCB
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.